Injex Pharma AG Announces Changes to It's Executive Management Board

BERLIN--(BUSINESS WIRE)--Injex Pharma AG announces the appointment of Dr. Thomas Klaue as member of the Executive Board with immediate effect. He will serve as the CEO of Injex Pharma AG. Andy Rösch, the founder and CEO to date, will retire at the end of June 2013. However, he will further support the company in the future as a consultant and as a main shareholder.

The Chairman of the Supervisory Board of Injex Pharma AG, Dr. Peter Heinrich, commented: 'On behalf of the Supervisory Board, I would like to thank Mr Andy Rösch for the impressive job he has done as a visionary founder and CEO in the start-up phase. His accomplishments are the basis for the growth phase we are facing now. And we are glad having been able to attract Mr Thomas Klaue, an experienced manager with capital markets expertise and with senior management experience in the technology and life science industry. He is the CEO to lead the company into the next growth stage and to the stock market.'

'After completion of the start-up phase I am looking forward to develop this company into the next stage. We will first reinforce our equity base and second increase our production capacity to supply our global distributor network', concluded the newly appointed Executive with regard to his new assignment.

The Harvard Business School graduate Thomas Klaue has more than two decades of experience as senior executive in the technology (EADS, Infineon Technologies) and biotech/healthcare industry, i. e. with MediGene AG. Since 2007 he served as CFO in listed companies and was appreciated by analysts and investors for his transparent communication with the capital market.

Injex Pharma AG is currently preparing its listing in segment General Standard at the Frankfurt Stock Exchange.

INJEX Pharma AG:

INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and INJEX Vertrieb Deutschland GmbH are specialized in the development, manufacturing and marketing in the medical technology segment and in the cosmetics and beauty markets. The Group's core business areas are the needle-free INJEX30 system and the product line SHIREEN in the beauty market. The main markets of the Group are North America, China, India, Russia and Europe.